Caribou Biosciences (NASDAQ:CRBU) Stock Rating Lowered by Leerink Partners

Caribou Biosciences (NASDAQ:CRBU) was downgraded by Leerink Partners from an “outperform” rating to a “market perform” rating in a research report issued on Wednesday, MarketBeat.com reports. They currently have a $1.00 target price on the stock. Leerink Partners’ target price suggests a potential upside of 117.30% from the stock’s previous close.

CRBU has been the subject of a number of other research reports. Royal Bank Of Canada cut Caribou Biosciences from an “outperform” rating to a “sector perform” rating and set a $1.00 target price for the company. in a report on Wednesday. Brookline Capital Markets cut Caribou Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday. Bank of America cut their price target on Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating for the company in a report on Friday, August 14th. Wall Street Zen cut Caribou Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Caribou Biosciences in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $5.50.

Caribou Biosciences Stock Down 4.4%

Shares of Caribou Biosciences stock traded down $0.02 during mid-day trading on Wednesday, reaching $0.46. 9,684,769 shares of the stock traded hands, compared to its average volume of 1,817,151. The business has a 50-day moving average of $1.43 and a 200 day moving average of $1.74. Caribou Biosciences has a fifty-two week low of $0.44 and a fifty-two week high of $3.54. The stock has a market capitalization of $49.34 million, a PE ratio of -0.43 and a beta of 2.31.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Thursday, August 13th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.08. Caribou Biosciences had a negative return on equity of 89.11% and a negative net margin of 1,030.42%.The business had revenue of $1.50 million during the quarter, compared to analysts’ expectations of $2.28 million. On average, equities research analysts expect that Caribou Biosciences will post -0.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Caribou Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in Caribou Biosciences during the second quarter worth $13,756,000. Bank of America Corp DE acquired a new stake in Caribou Biosciences during the second quarter worth $2,483,000. Renaissance Technologies LLC increased its stake in Caribou Biosciences by 58.0% during the first quarter. Renaissance Technologies LLC now owns 2,590,497 shares of the company’s stock worth $4,922,000 after acquiring an additional 950,640 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Caribou Biosciences during the second quarter worth $816,000. Finally, Green Alpha Advisors LLC acquired a new stake in Caribou Biosciences during the second quarter worth $641,000. Institutional investors and hedge funds own 77.51% of the company’s stock.

More Caribou Biosciences News

Here are the key news stories impacting Caribou Biosciences this week:

• Positive Sentiment: Leerink Partners set a $1.00 price target, substantially above the recent trading level, suggesting potential upside if Caribou’s clinical and business outlook improves. However, the firm simultaneously downgraded the stock to “Market Perform.” Leerink Partners Downgrades Caribou Biosciences to Market Perform
• Neutral Sentiment: HC Wainwright downgraded Caribou from “Buy” to “Neutral” and issued forecasts for continued losses through 2027: $(0.11) EPS in the first quarter, $(0.08) in the second, $(0.07) in the third and $(0.05) in the fourth. The estimates imply gradual improvement but no near-term profitability. HC Wainwright Downgrades Caribou Biosciences to Neutral
• Neutral Sentiment: Reported short interest totaled zero shares as of October 9, producing a zero-day days-to-cover ratio. This indicates no measurable short-position overhang in the reported data, although the figure may reflect a reporting anomaly rather than a meaningful change in investor positioning.
• Negative Sentiment: Brookline Capital Markets also downgraded Caribou to “Hold,” adding to the recent wave of more cautious analyst opinions. Brookline Capital Markets Downgrades Caribou Biosciences to Hold
• Negative Sentiment: A MedCity News report described Caribou’s off-the-shelf cell-therapy effort as reaching the “end of the road,” raising concerns about the company’s pipeline, future catalysts and ability to create shareholder value. Caribou Bio’s Journey With Off-the-Shelf Cell Therapy Reaches the End of the Road

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient.

Caribou’s research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA.